[go: up one dir, main page]

MXPA06012960A - Administracion transdermal de ficotoxinas. - Google Patents

Administracion transdermal de ficotoxinas.

Info

Publication number
MXPA06012960A
MXPA06012960A MXPA06012960A MXPA06012960A MXPA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A MX PA06012960 A MXPA06012960 A MX PA06012960A
Authority
MX
Mexico
Prior art keywords
propinoperhydropurine
tricyclic
effective amount
pharmaceutical compositions
transdermal
Prior art date
Application number
MXPA06012960A
Other languages
English (en)
Inventor
Nestor Antonio Lagos Wilson
Original Assignee
Phytotox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotox Ltd filed Critical Phytotox Ltd
Publication of MXPA06012960A publication Critical patent/MXPA06012960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Se describen composiciones farmaceuticas para interferir con la transmision neuronal que comprenden una cantidad efectiva de por lo menos una 3,4-propinoperhidropurina triciclica; se proporcionan preparaciones para rejuvenecimiento facial que comprenden un cantidad efectiva de la composicion de la invencion y una crema facial; se proporcionan metodos para interferir con la transmision neuronal que comprenden la aplicacion topica de una cantidad efectiva de las composiciones farmaceuticas de la invencion; en otro aspecto de la invencion, se proporcionan cantidades efectivas de las composiciones farmaceuticas y un sistema terapeutico transdermico para la administracion transdermica de por lo menos una 3,4-propinoperhidropurina triciclica; la composicion farmaceutica comprende por lo menos una 3,4-propinoperhidropurina triciclica; y pueden formularse para suministro transdermico del farmaco; el sistema de suministro transdermico del farmaco puede ser un material compuesto laminado que comprende una capa de soporte, un deposito de farmaco y un medio para fijar el material compuesto a la piel.
MXPA06012960A 2004-05-07 2005-05-06 Administracion transdermal de ficotoxinas. MXPA06012960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56911204P 2004-05-07 2004-05-07
PCT/US2005/015819 WO2005110418A2 (en) 2004-05-07 2005-05-06 Transdermal administration of phycotoxins

Publications (1)

Publication Number Publication Date
MXPA06012960A true MXPA06012960A (es) 2007-06-12

Family

ID=35394660

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012960A MXPA06012960A (es) 2004-05-07 2005-05-06 Administracion transdermal de ficotoxinas.

Country Status (10)

Country Link
US (1) US8377951B2 (es)
EP (1) EP1796676B1 (es)
JP (1) JP2007538010A (es)
CN (1) CN101123967A (es)
AU (1) AU2005244096B2 (es)
BR (1) BRPI0510760A (es)
CA (1) CA2607206C (es)
ES (1) ES2568953T3 (es)
MX (1) MXPA06012960A (es)
WO (1) WO2005110418A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2821239C (en) * 2004-05-07 2016-04-12 Phytotox Limited Phycotoxins and uses thereof
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009143174A2 (en) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Chemical permeation enhancers enhance nerve blockade by toxins
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
WO2010117996A1 (en) * 2009-04-08 2010-10-14 Children's Medical Center Corporation Prolonged duration local anesthesia with minimal toxicity
JP6186125B2 (ja) * 2009-05-07 2017-08-30 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 疼痛の研究、画像化および治療方法、ならびに疼痛の研究、画像化および治療のための組成物
EP2533785B1 (en) 2010-02-10 2014-04-23 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
MX367393B (es) * 2012-02-17 2019-08-16 Veloce Biopharma Llc Composiciones antifungicas para el tratamiento de piel y uñas.
EP2638908A1 (en) * 2012-03-16 2013-09-18 Phytotox SpA Paralytic Shellfish Poison
CA2867511A1 (en) * 2012-03-22 2013-09-26 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
HRP20190419T1 (hr) 2013-03-15 2019-05-03 The Children's Medical Center Corporation Kombinacijske formulacije neosaksitoksina za produženu lokalnu anesteziju
AU2015243437B2 (en) 2014-04-09 2019-08-29 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins useful for the treatment of pain
US10112953B2 (en) 2015-09-30 2018-10-30 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
JP7090100B2 (ja) 2017-03-29 2022-06-23 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３－修飾サキシトキシン：
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
US11338308B2 (en) 2018-08-09 2022-05-24 Kao Corporation Method for producing wearable coating
US12162886B2 (en) 2018-10-03 2024-12-10 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957966A (en) * 1972-05-19 1976-05-18 Gaf Corporation Stabilized vitamin food coatings
US4022899A (en) * 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029794A (en) * 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US4001413A (en) * 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5246705A (en) 1992-04-08 1993-09-21 Cygnus Therapeutic System Occlusive, elastomeric backing materials in transdermal drug delivery systems, and associated methods of manufacture and use
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
AU2431995A (en) * 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
JP3517031B2 (ja) * 1995-06-09 2004-04-05 日清紡績株式会社 生物学的活性物質の分析法
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CN1081034C (zh) 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
WO1998043619A2 (en) 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
DK2145629T3 (da) * 1997-07-15 2012-05-29 Univ Colorado Regents Anvendelse af neurotoksinterapi til behandling af urologiske og relaterede sygdomme
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
CA2347828A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6299902B1 (en) 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
CN1240702C (zh) * 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
CN1382443A (zh) * 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
EA006739B1 (ru) * 2001-11-15 2006-04-28 Майкроу Элджи Корпорейшн Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
CN1194693C (zh) 2002-01-11 2005-03-30 中国科学院海洋研究所 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用
AU2003231878A1 (en) 2002-05-31 2003-12-19 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050202093A1 (en) * 2002-12-02 2005-09-15 Kohane Daniel S. Prolonged suppression of electrical activity in excitable tissues
CA2821239C (en) * 2004-05-07 2016-04-12 Phytotox Limited Phycotoxins and uses thereof

Also Published As

Publication number Publication date
CN101123967A (zh) 2008-02-13
EP1796676A2 (en) 2007-06-20
US20080045553A1 (en) 2008-02-21
WO2005110418A3 (en) 2007-06-07
WO2005110418A2 (en) 2005-11-24
US8377951B2 (en) 2013-02-19
HK1109332A1 (zh) 2008-06-06
BRPI0510760A (pt) 2007-11-20
EP1796676B1 (en) 2016-03-09
CA2607206A1 (en) 2005-11-24
AU2005244096A1 (en) 2005-11-24
ES2568953T3 (es) 2016-05-05
JP2007538010A (ja) 2007-12-27
AU2005244096B2 (en) 2011-03-17
EP1796676A4 (en) 2008-06-25
CA2607206C (en) 2016-06-14

Similar Documents

Publication Publication Date Title
MXPA06012960A (es) Administracion transdermal de ficotoxinas.
Sorge et al. Transdermal buprenorphine in the treatment of chronic pain: resultsof a phase III, multicenter, randomized, double-blind, placebo-controlled study
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
TW200612987A (en) Combination treatment for non-hematologic malignancies
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2005051297A3 (en) Combination drug therapy to treat obesity
WO2007092284A3 (en) Low dose no donor-containing transdermal patch
WO2011029948A3 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
MX2009014102A (es) Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea.
AR056453A1 (es) Composiciones con estrogeno y metodos terapeuticos para su uso
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
AU2003215657A1 (en) Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
WO2008116004A3 (en) Transdermal patch and method for delivery of vitamin b12
WO2006012213A3 (en) Composition and method for delivery of phytochemicals
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
WO2005117871A3 (en) Pharmaceutical compositions for the treatment of pruritus
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
MX2010009578A (es) Metodos para incrementar el espesor epidermico de la piel mediante la administracion topica de un compuesto de vitamina d que contiene 19-nor.
WO2010057117A3 (en) Topical transdermal drug delivery compositions
WO2007133514A3 (en) Photosensitizer formulations for topical applications